LUNGevity Foundation shared a post on LinkedIn:
“Precision lung cancer care is advancing rapidly, driven by a deeper understanding of the disease biology, identification of additional actionable biomarkers, and validation and regulatory approval of a growing list of targeted therapies.
With this unprecedented progress comes new challenges related to testing and treatment in community and academic oncology practice.
View this PVI, PeerView Institute for Medical Education activity, recorded at ASCO 2025 and produced in partnership with the Oncology Brothers, for insights on actionable alterations in NSCLC, practical biomarker testing strategies, and evidence-based selection and sequencing of targeted therapies from early through advanced disease.
Watch now to strengthen your skills in delivering precision lung cancer care to your patients with NSCLC.”
More posts featuring LUNGevity Foundation.